MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
25.29
-0.48
-1.86%
After Hours: 25.40 +0.11 +0.44% 18:03 12/18 EST
OPEN
25.99
PREV CLOSE
25.77
HIGH
26.16
LOW
24.97
VOLUME
476.22K
TURNOVER
--
52 WEEK HIGH
30.50
52 WEEK LOW
14.40
MARKET CAP
1.68B
P/E (TTM)
-7.4783
1D
5D
1M
3M
1Y
5Y
1D
Celldex Therapeutics Is Maintained at Underweight by Barclays
Dow Jones · 1d ago
Celldex Therapeutics Price Target Raised to $24.00/Share From $21.00 by Barclays
Dow Jones · 1d ago
Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24
Benzinga · 1d ago
Celldex (CLDX) Receives a Sell from Barclays
TipRanks · 1d ago
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 3d ago
Weekly Report: what happened at CLDX last week (1208-1212)?
Weekly Report · 3d ago
Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
TipRanks · 4d ago
Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
TipRanks · 4d ago
More
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.